A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction

Naomi Fischer, Elad Moisseiev*, Michael Waisbourd, Michaella Goldstein, Anat Loewenstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: The study reported here investigated the rates of systemic serious adverse events (SAEs) following treatment with intravitreal bevacizumab for age-related macular degeneration (AMD) in comparison with a matched control group. Methods: A retrospective age-and sex-matched case-control design was used. Data were col-lected using patient charts and telephone surveys. The main outcome measure was difference in number of hospital admissions between the two groups. Hospitalizations were further analyzed according to whether or not they were due to arteriothrombotic SAEs. Results: Each group comprised 65 participants. There were significantly more hospital admis-sions among bevacizumab-treated patients than in the control group (P = 0.039). Sub-analysis of hospitalizations due to arteriothrombotic causes did not reveal a statistically significant difference between groups (P = 0.629). Conclusion: The results suggest that intravitreal bevacizumab is not associated with an increased risk of arteriothrombotic SAEs. Its widespread use for the treatment of AMD appears to be systemically safe.

Original languageEnglish
Pages (from-to)621-625
Number of pages5
JournalClinical Ophthalmology
Volume7
DOIs
StatePublished - 25 Mar 2013

Keywords

  • Avastin®
  • Safety
  • Serious adverse events

Fingerprint

Dive into the research topics of 'A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction'. Together they form a unique fingerprint.

Cite this